Berzosertib: clinical trials and development status

NLM verified identityNot approved in the USNo EMA authorisation

As of 30 October 2026 Berzosertib is in 11 active clinical trials (recruiting or ongoing, phases I–III) for 13 diseases. The most advanced phase is II.

11Active trials

IIMost advanced phase

13Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Berzosertib and get an email at every change or safety alert.

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

Disease	Most advanced phase	Active trials	Reference trial
Lung small cell carcinoma	II	4	NCT03896503
Lung neoplasm	I–II	3	NCT04216316
Fallopian tube neoplasm	II	2	NCT02595892
Metastasis	I–II	2	NCT04266912
Ovarian neoplasm	II	2	NCT02595892
Prostatic Neoplasms	II	1	NCT03517969
Brain Neoplasms	I	1	NCT02589522
Breast neoplasm	I	1	NCT04052555
Colorectal neoplasm	I	1	NCT02595931
Head and neck squamous cell carcinoma	I	1	NCT02567422
Non-small-cell lung carcinoma	I	1	NCT02589522
Pancreatic neoplasm	I	1	NCT02595931
Triple-negative breast neoplasm	I	1	NCT04052555

Everything on Berzosertib

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

Italiano Français Deutsch